Valuation
- Market cap
- 265,000
- Revenue TTM
- $180,000
- Net income TTM
- $-3,070,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -1,705.56%
- Debt to equity
- -0.70
Trading
- Volume
- 15,000
- Avg volume
- 44,274
- Day's range
- $0.00 – $0.00
- Shares out
- 132,366,000
- Stochastic %K
- 0%
- Beta
- 0.26
- Analysts
- —
- Price target
- $0.15
Company profile
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of treatments targeting unmet needs in infectious diseases in the United States and Canada. The company offers LIKMEZ (ATI-1501), a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial and protozoal infections. It also develops ATI-1801, a topical formulation of paromomycin...
Show more
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of treatments targeting unmet needs in infectious diseases in the United States and Canada. The company offers LIKMEZ (ATI-1501), a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial and protozoal infections. It also develops ATI-1801, a topical formulation of paromomycin in a Phase III trial for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine in preclinical trials for the prevention of Francisella tularensis infection. The company has a collaboration with Vitalex Biosciences to advance VXV-01, a dual-antigen vaccine targeting invasive Candida infections. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 902-442-4655
- Website
- https://appilitherapeutics.com
- Address
- 1344 Summer Street, Suite 21, Halifax, Canada
Latest news
No headlines yet.
